Bio-Rad's Narrow Green Shoot: ddPCR Grows, the Rest Still Drags
A first quarter of currency-neutral growth and a $50 million impairment land in the same print — while the market has already run 29% ahead of a reaffirmed guide
BIO · Earnings Call · 2026-11-04
The green shoot has a narrow stem
Bio-Rad's Q3 2026 report is the first in a while that management can call an improvement without squinting. Revenue was about $656 million, up 0.5% reported and 0.7% currency-neutral; non-GAAP gross margin rose to 54.5% and non-GAAP operating margin to 12.8%. Jonathan DiVincenzo called it “our first quarter of currency-neutral growth this year” — Jonathan DiVincenzo, President · 2026-11-04. The stock has noticed: BIO is up 29.4% over the last 90 trading days, even though it remains roughly 54% below its 2021 peak. The report is better. It is not yet a broad recovery. Clinical diagnostics returned to growth, up 2.7% reported, but the drivers were quality systems, diabetes products and order timing in China — not a sudden diagnostics upcycle. Life Sciences was still down 2.8%, and excluding process chromatography, it grew only 2.5%. Roop Lakkaraju framed the mix bluntly: “This is primarily driven by lower process chromatography sales and ongoing challenges in the academic research market” — Roop K. Lakkaraju, Executive Vice President · 2026-11-04. The academic market remains the soft spot: NIH outlays fell about 15% in Q3 and finished the fiscal year roughly $6 billion below congressional appropriations, and Q4 guidance assumes no recovery in academic and government demand. The company-unique growth vector is Droplet Digital PCR. ddPCR instrument revenue rose more than 20% for a third straight quarter, and the total ddPCR portfolio grew 7% currency-neutral, helped by qPCR conversions and competitive wins. But consumable pull-through has not normalized and may not until 2027. That is the key lag: placements are working, revenue per installed system is not yet. Management had already pre-framed the ceiling on the process chrom franchise in the prior call: “low to mid-single-digit near-term growth rate from a process chromatography standpoint” — Roop Lakkaraju, Chief Financial Officer or Senior Finance Executive · 2026-08-04. The installed-base story is good — but it is a slower P&L story than the share price implies.What changed — and what quietly slipped
Two items are genuinely new-ish. First, Bio-Rad recorded a roughly $50 million non-cash impairment of purchased intangible assets in Life Sciences. “During the quarter, we also recorded a non-cash impairment of approximately $50 million related to purchased intangible assets in the Life Sciences segment” — Roop K. Lakkaraju, Executive Vice President · 2026-11-04. That is portfolio discipline, but it is also an admission that some acquired technology is not earning its keep. Second, the restructuring clock moved. Management reiterated the $80–$90 million program and $30–$35 million of net savings, but the full effect is now a 2028 event:That contrasts with the prior call, when Roop said “we anticipate getting it all done by the end of '27 at the latest” — Roop Lakkaraju, Chief Financial Officer or Senior Finance Executive · 2026-08-04. A slip in restructuring savings matters because 2027 margin expansion is central to the turnaround case. Tariffs are the third moving part. Bio-Rad took no tariff-refund benefit in Q3 and expects to recognize refunds at year-end; they will be GAAP-only and excluded from non-GAAP. “Our 3rd quarter results do not include any benefit from tariff refunds. In our year-end results, we expect to recognize any tariff refunds that we receive” — Roop K. Lakkaraju, Executive Vice President · 2026-11-04. That is a real tariff refunds option — and it is not company-specific: tariff-refund language is showing up across the global tape and among other reporters this season. But it is a one-time cash/GAAP item, not an operating margin fix. The odd omission is China's reimbursement reset. A quarter ago management said of the NHSA cost-containment push, “to date, we're not seeing anything impacting us” — Roop Lakkaraju, Chief Financial Officer · 2026-05-01. This quarter it is quantified — a middle single-digit millions revenue impact in 2027 from the updated guidelines. That is a small number, but it is a directional reversal of the prior "no impact" framing, and it arrives in the same quarter China "returned to growth" largely on order timing.The $30 to $35 million is still intact... the actions will take hold throughout the latter part of '26 and throughout '27. And as such, the full realization of that 30 to 35 will really be in full effect starting in '28.
The market is ahead of the guide
BIO's 90-day tape is a +29% straight line into the print. Meanwhile guidance was reaffirmed, not raised: full-year currency-neutral revenue still -3% to +0.5%, Life Sciences -3% to -1%, Diagnostics -3% to +1%. Q4 includes a sequential decline in process chromatography plus higher fuel and a mix shift toward instruments. Roop: “We expect a sequential decline in the 4th quarter due to product mix shifting more toward instruments. The expected sequential decline in process chromatography revenue and higher fuel prices” — Roop K. Lakkaraju, Executive Vice President · 2026-11-04. That is not a clean beat-and-raise setup, and the analyst pushback on 2027 started on the first question of the call — with management offering only "positive growth" as a directional breadcrumb. Valuation is no longer distressed. Bio-Rad trades at 3.0x revenue, with a gross margin that has drifted from the low-50s toward 53-54% on a non-GAAP basis. It also carries $1.4 billion of effective net cash, which is why Sartorius and M&A keep coming up. Roop called Sartorius “a monetizable asset” — Roop K. Lakkaraju, Executive Vice President · 2026-11-04 and said Bio-Rad would act if a sensible scenario appeared; M&A targets remain $100–$500 million of revenue in diagnostics or life-science tools. Norman Schwartz added that the Elliott dialogue is “active and productive” — Norman Schwartz, Chairman and Chief Executive Officer · 2026-11-04 and that the board is evaluating adding operational experience. That supports the stock, but it is not an operating result.Put together, this is an early-turn report with a narrow base: diagnostics and ddPCR are growing, process chromatography and academic funding are still drags, and the restructuring and tariff catalysts are back-ended. Free cash flow through nine months was $210 million against a reiterated $290–$340 million full-year target, so Q4 has to deliver — $52 million of quarterly free cash flow is the run-rate that must accelerate. The stock has already voted for the turnaround; the next quarter has to show operating leverage, not just the narrative.We continue to firmly believe that Bio-Rad is capable of delivering operating margins above 20%. We're not satisfied with the gap between our current performance and that potential.